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Abstract
Purpose This study aimed to report the practice of managing
breast cancer with bone metastasis in Turkey and to determine
the adherence to the British Association of Surgical Oncology
(BASO) guidelines.
Methods This multicenter, cross-sectional epidemio-
logical survey was conducted in 38 centers across
Turkey. Data from 1,026 breast cancer patients with
bone metastases (mean age 54.0±11.9 years) were
analyzed.
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Results Over 30 % of patients had a diagnosis of metastatic
breast cancer (stage IV) at the time of primary diagnosis.
The imaging modalities used for diagnosing bone metasta-
ses were bone scintigraphy (57.8 %), radiography (22.8 %),
and bone survey (4.4 %). Tumor markers were detected in
94.9 %, and markers of bone metabolism were measured in
90.4 % of patients. A total of 3.5 % of patients underwent
surgery for bone metastasis, 26.4 % underwent palliative
chemotherapy (most commonly docetaxel+capecitabine),
and 56.5 % endured radiotherapy. Most patients (96 %)
also received bisphosphonate. Radiography, bone scintigra-
phy, and CT were the main imaging tools used for postop-
erative follow-up of bone metastasis. Our results were
>95 % in line with the BASO guidelines for the manage-
ment of bone metastasis, except that interventional proce-
dures, such as biopsy, were applied less frequently in our
survey.
Conclusions The diagnosis and management practices of
breast cancer with bone metastasis in Turkey were generally
compatible with international guidelines. However, the aware-
ness and knowledge of physicians on the current guidelines
should be increased, and equipment for the appropriate inter-
ventional procedures should be provided in every clinic to
obtain optimal and standard management of bone metastases.
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Introduction
Breast cancer is the most common malignancy in females in
Turkey and worldwide. According to the Turkish Ministry of
Health statistics, the estimated incidence of breast cancer was
41.6 per 100,000 in 2008, which has increased gradually over
the last 5 years [1]. Breast cancer frequently metastasizes to
the bone, and around 70 % of patients with recurrent breast
cancer have bone metastasis, a common cause of morbidity
and mortality [2–4].
In spite of the recent advances in our understanding of the
pathology of breast cancer and bone metastasis and in cancer
therapy, the management of breast cancer patients with bone
metastasis remains complex and challenging. However, the
early diagnosis of metastatic breast cancer and optimization of
systemic therapies in combination with optimal local treat-
ment can increase patient survival [5–7]. Therefore, the pres-
ence and clinical implementation of the practical guidelines
are crucial for the effective management of metastatic breast
cancer. Although several international and national guidelines
exist for early stage breast cancer [8–10], there are a limited
number of international guidelines for metastatic breast can-
cer, particularly for the management of bone metastasis from
breast cancer. One example is the British Association of
Surgical Oncology (BASO) guidelines [11, 12].
The current management practices for breast cancer pa-
tients with bone metastasis in Turkey have not been assessed
in a comprehensive epidemiological study. Furthermore, there
are no widely accepted standardized national guidelines that
are followed. Data identifying the current clinical approach to
these patients in daily practice and the rate of compliance to
international guidelines would provide a basis for developing
national guidelines and policies for the management of breast
cancer patients with bone metastasis.
In this study, we aimed to report the current practice for the
diagnosis and management of breast cancer patients with bone
metastasis in Turkey and to determine the compatibility of
these practices with the BASO guidelines for the management
of metastatic bone disease in breast cancer [11].
Materials and methods
Study design and population
This was a multicenter, cross-sectional epidemiological sur-
vey performed in cancer patients with bonemetastasis from 38
centers across Turkey between December 2010 and June
2011. Patients >18 years old with histologically diagnosed
breast cancer, radiologically proven bonemetastasis, and a life
expectancy >6 months were enrolled in the study. Pregnant or
nursing patients were excluded.
The study was approved by the Inönü University Medical
Faculty Ethics Committee and was conducted in accordance
with the Helsinki Declaration and local requirements. All
patients provided informed consent before participation in
the study.
Study procedures
Patients were evaluated for the practical approaches used
for the diagnosis, treatment, and follow-up of bone metas-
tasis in each center. The following information was record-
ed for evaluation: physical examination methods, radiolog-
ical tools, interventional techniques, pathology and labora-
tory methods used for diagnosis, surgical approaches, che-
motherapy, radiotherapy, bisphosphonates, supportive treat-
ment, and other treatment regimens. Follow-up data were
collected from three consecutive visits after the initial ther-
apy. The duration of follow-up, the frequency of visits, the
methods used for bone metastasis follow-up, and any
changes (with reasons) to the treatment plan were recorded.
We then determined the adherence to the BASO guidelines
[11] separately for four aspects of care for metastatic bone
disease: diagnosis, staging, treatment, and assessment of the
response to treatment.
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Statistical analysis
Sample size calculation was based on the hypothesis that the
management practices of bone metastasis in breast cancer
patients in Turkey showed 100 % adherence to the BASO
guidelines. To determine this adherence rate with 0.2 % error,
the sample size was calculated as 1,250 patients when the type
1 error was 0.05, type 2 error was 0.10 (power 90 %), and the
dropout rate was 20 %.
Study data were summarized with descriptive statistics
(such as frequency, percentage, mean, standard deviation,
and range). Categorical variables were analyzed using chi-
square and Fisher’s exact tests, and ordinal variables were
analyzed using the Mantel-Haenszel test. For continuous var-
iables, the paired sample t test and Wilcoxon test were per-
formed for normally and non-normally distributed data, re-




A total of 1,038 patients were enrolled in the study. Twelve
patients were excluded from the analysis due to insufficient
data (n=10) or not meeting the study selection criteria (n=2).
Therefore, the final analysis was performed on data from
1,026 patients (mean age 54.0±11.9, range 22.4–87.2 years).
Of these patients, 801 (78.1 %) were premenopausal, and 225
(21.9 %) were postmenopausal. The most common histolog-
ical type of breast cancer was ductal carcinoma (n=845,
82.4 %).
Breast cancer history
The most common reasons for the referral of patients to the
attending physician were masses detected on self-examination
(n=505, 49.2 %), on physical examination (n=215, 21.0 %),
and on radiological evaluation (n=78, 7.6 %), as well as bone
pain (n=61, 6.9 %). At diagnosis, the primary breast tumor
was >2 cm (≥T2 stage) in 70.1 % of patients, had spread to at
least one axillary lymph node or internal mammary lymph
node (N1 stage and over) in 50.6 %, and metastasized to
distant organs in 33.3 % of patients. All patients had bone
metastasis that was diagnosed 1.3±1.8 years before enroll-
ment into the present survey (Table 1).
Diagnosis of bone metastasis
The most common imaging modality for diagnosing bone
metastasis was bone scintigraphy, followed by direct radiog-
raphy. Bone biopsy and fine-needle aspiration biopsy were
used as the diagnostic methods in only 46 patients (4.5 %).
Tumor markers were detected in 974 patients (94.9 %), and
bone metabolism markers (e.g., AP, Ca2+) were measured in
927 (90.4%). The use of diagnostic tests for bonemetastasis is
summarized in Table 2.
Treatment of bone metastasis
Of the 1,026 patients, 36 (3.5 %) underwent surgery, 26.4 %
palliative chemotherapy, 56.5 % radiotherapy, and 10.4 % hor-
monal therapy for bone metastasis. Docetaxel+capecitabine
was the most common regimen for palliative chemotherapy of
bonemetastasis.Most patients (96%) received bisphosphonate,
typically ibandronic acid and zoledronic acid (Table 3).
Follow-up after breast tumor surgery
The bone metastases were followed up postoperatively with
radiological modalities and biochemical testing. The major
imaging tools used were radiography, bone scintigraphy, and
CT (Table 4).
Compatibility of survey results with the BASO guidelines
Our results were >95 % consistent with the BASO guidelines
for the management of metastatic bone disease in breast
cancer in the UK, for the use of radiological methods and
laboratory tests for the diagnosis and staging of bone
Table 1 Breast cancer diagnosis history of study patients (n=1,026)
Mean±SD (range) or n (%)
Time since diagnosis of breast cancer (years) 4.1±4.0 (0.0–22.7)
Time since diagnosis of bone metastasis (years) 1.3±1.8 (0.0–13.7)
TNM staging at diagnosis
T (primary tumor) T0 1 (0.1 %)
T1 140 (13.6 %)
T2 457 (44.5 %)
T3 147 (14.3 %)
T4 116 (11.3 %)
N (lymph nodes) N0 120 (11.7 %)
N1 218 (21.2 %)
N2 202 (19.7 %)
N3 101 (9.8 %)
M (metastasis) M0 612 (59.6 %)
M1 342 (33.3 %)
Stage grouping at diagnosis Stage I 44 (4.3 %)
Stage II 267 (26 %)
Stage III 331 (32.3 %)
Stage IV 346 (33.7 %)
SD standard deviation
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metastasis, and for the use of chemotherapy and hormonal
therapy for bone metastasis. In contrast, interventional proce-
dures, such as biopsy, for diagnosing bone metastasis and
surgical treatment were applied to a much lesser extent in
our survey than recommended by the BASO guidelines
(Table 5).
Discussion
In this large, cross-sectional, epidemiological survey, we ana-
lyzed the current clinical practice for the diagnosis and man-
agement of breast cancer patients with bone metastasis in
Turkey. Our study population included breast cancer patients
with bone metastasis; ~30 % had bone metastasis at initial
Table 2 Tests for diagnosis and staging evaluation of bone metastasis
Number (%)
Imaging modalities for diagnosis




Bone surveya 124 (12.1)
Others 172 (16.8)
Interventional procedures for diagnosis
Bone biopsy 36 (3.5)
Fine-needle aspiration biopsy 10 (1.0)
Others 53 (5.2)
None 932 (90.8)
Biochemical tests for diagnosis
Tumor markers (CEA, Ca15.3) 974 (94.9)
Markers of bone metabolism 927 (90.4)
Markers of bone resorption 158 (15.4)
Markers of bone remodeling 134 (13.1)
Others 22 (2.1)
Imaging modalities for staging
Bone scintigraphy 868 (84.6)
CT 685 (66.8)




Biochemical tests for staging
Liver function tests 1,009 (98.3)
Renal function tests 994 (96.9)
Complete blood count 980 (95.5)
Markers of bone metabolism 921 (89.8)
Others 33 (3.2)
a Bone survey is a series of X-ray of the major bones (axial or cortical
bones) in the body
Table 3 Management of bone metastasis
Treatment of bone metastasis Number (%)
Surgery 36 (3.5)
Stabilization and reconstruction of pathologic fractures 20 (55.6)
Prophylactic fixation of metastatic region
with fracture risk
9 (25.0)
Decompression of vertebral fractures 2 (5.6)
Others 5 (13.9)












Goserelin acetate 2 (1.9)
Combination regimens 20 (18.7)
Other treatment (bisphosphonate) 985 (96.0)
Ibandronic acid 567 (57.6)
Zoledronic acid 266 (27.0)
Zoledronic acid+ibandronic acid 111 (11.3)
Others 41 (4.2)
Table 4 Follow-up modalities for bone metastasis after breast tumor
surgery
Visit 2 Visit 3 Visit 4
n (%) n (%) n (%)
Radiology
Radiography 109 (37.2) 79 (31.5) 95 (35.3)
Bone scintigraphy 114 (38.9) 84 (33.5) 85 (31.6)
CT 84 (28.7) 92 (36.7) 96 (35.7)
MRI 34 (11.6) 41 (16.3) 40 (14.9)
Bone surveya 13 (4.4) 11 (4.4) 12 (4.5)
Others 37 (12.6) 31 (12.4) 40 (14.9)
Laboratory
Complete blood count 860 (97.3) 815 (97.0) 802 (98.0)
Renal function tests 826 (93.4) 782 (93.1) 765 (93.5)
Liver function tests 811 (91.7) 773 (92.0) 764 (93.4)
Markers of bone metabolism 772 (87.3) 734 (87.4) 724 (88.5)
Tumor markers 698 (79.0) 700 (83.3) 691 (84.5)
Others 8 (0.9) 7 (0.8) 3 (0.4)
a Bone survey is a series of X-ray of the major bones (axial or cortical
bones) in the body
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diagnosis, and the rest were diagnosed during the course of the
disease. We focused primarily on the diagnosis and treatment
of bone metastasis. The findings of the present survey indi-
cated that the practical approach to breast cancer patients with
bone metastasis in Turkey was consistent with international
guidelines; discrepancies are likely due to insufficient knowl-
edge of the guidelines by physicians and to the lack of equip-
ment at some centers.
Patient-related and disease-related factors, the incurable
nature of the disease, and difficulty in implementing the
available knowledge in clinical practice complicate the diag-
nosis and treatment of bone metastases, which cause signifi-
cant mortality in breast cancer patients [13]. Therefore, bone
metastasis of breast cancer is frequently late or misdiagnosed
and poorly treated. Nevertheless, timely diagnosis and effec-
tive treatment increase patient survival [5–7]. To overcome the
obstacles for managing breast cancer that has metastasized to
the bone, several guidelines were developed. The BASO
guidelines are international guidelines developed by a multi-
disciplinary group of specialists for the management of met-
astatic bone disease in breast cancer [11]. These guidelines
consider all aspects of care of metastatic bone disease in breast
cancer patients, including diagnosis, staging, treatment, and
assessing the response to treatment. A recent consensus guide-
line was published following the First International Consensus
Conference for Advanced Breast Cancer in 2011, which fo-
cused primarily on metastatic breast cancer and suggested a
multidisciplinary approach [12].
In these guidelines, radiological, laboratory, and interven-
tional assessments were recommended for diagnosing bone
metastasis in patients with persistent and localized bone pain,
depending on the level of clinical suspicion [11, 12]. In our
survey, the most common modalities for diagnosing bone
metastasis were bone scintigraphy followed by radiography.
Because radiological techniques give reliable results and bi-
opsies are interventional modalities that cause patient discom-
fort and that are not universally available, bone biopsy and
fine-needle aspiration biopsy were applied in only 3.5 % of
patients. Tumor markers (CEA, Ca15.3) were detected in
94.9 % of patients as a part of routine oncologic diagnostic
procedures for the origin of bone metastasis, and markers of
bone metabolism were measured in 90.4 % of patients.
The treatment of bone metastasis derived from breast can-
cer includes antitumor endocrine and cytotoxic agents, radio-
therapy, bisphosphonates, and conservative treatments [14].
The interaction between tumor cells and the bone microenvi-
ronment is the main molecular mechanism underlying bone
metastasis in breast cancer [15, 16]. Novel therapies based on
recent advances in molecular biology were developed recently
to prevent and treat bone metastasis in breast cancer [15, 17];
however, they are not yet widely used in clinical practice.
According to the BASO guidelines, optimum treatment of
metastatic bone disease should be aimed at identifying pa-
tients who are at risk of fracture and identifying prophylactic
treatment [11]. Surgery should be performed as prophylactic
fixation of metastatic deposits when there is a risk of fracture,
for stabilization or reconstruction following pathological frac-
ture, and for decompressing the spinal cord and nerve roots
followed by stabilization of the affected vertebra. Of the
patients in our survey, only 3.5 % underwent surgery for bone
metastasis, compared with 56.5 % who received radiotherapy.
The low rate of surgery may be due to an insufficient multi-
disciplinary approach, including the lack of orthopedic sur-
geons and neurosurgeons involved in the management of bone
metastasis; this should be improved. Although the rate of
radiotherapy was higher, it was still less than suggested.
In the literature, several studies have shown a survival
benefit from treatment of metastastic breast cancer with che-
motherapy; however, most optimum regimen to delay or
prevent the development of bone metastases has not been
defined [18–20]. In the current survey, 26.4 % of patients
received palliative chemotherapy; the most common regimen
was docetaxel in combination with capecitabine. Neverthe-
less, the management practices for bone metastasis in our
survey were >95 % compliant with the BASO guidelines,
with the exception of the interventional diagnostic and treat-
ment procedures such as biopsy and surgery, which were
applied to a much lesser extent in our survey than is recom-
mended by the guidelines [11, 12].
Newer and more efficacious generation of bisphosphonates
currently forms the gold standard for treating bone metastasis
[14, 17, 21]. Bisphosphonates have antiresorptive action and
reduce tumor-associated osteolysis by inhibiting osteoclast
function in bone metastases. Furthermore, bisphosphonates
can alleviate bone pain in patients with bone metastasis. The
effectiveness of bisphosphonates in reducing pain and




Diagnosis of bone metastasis
Radiology 977 (95.2)








Chemotherapy or hormonal therapy 997 (97.2)
Methods to evaluate the response to bone metastasis therapy 885 (86.3)
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increasing quality of life has been recognized in randomized
clinical trials [14, 21, 22]; as such, the guidelines suggest that
they be used routinely in combination with other systemic
therapies in breast cancer patients with bone metastasis [12].
Consistent with the guidelines, most of the patients (96 %) in
our survey received bisphosphonates, most commonly
ibandronic acid and zoledronic acid. For the postoperative
follow-up of bone metastasis, radiography, bone scintigraphy,
and CT were three main imaging tools, consistent with the
BASO guidelines [11].
In conclusion, the diagnosis and management practices of
breast cancer that has metastasized to the bone in Turkey are
generally compatible with international guidelines. However,
the awareness and knowledge of physicians regarding the
current guidelines should be enhanced, and the equipment
necessary to perform interventional procedures should be
provided to all clinics to achieve optimal and standard man-
agement of bone metastasis in breast cancer. A multidisciplin-
ary approach including radiation oncologists, medical oncol-
ogists, orthopedic surgeons, neurosurgeons, and radiologists
is crucial to achieve the optimum therapeutic approach for
bone metastasis; such should be improved in Turkey. A na-
tional policy should be developed and implemented to provide
the optimum care and to subsequently increase survival and
quality of life of breast cancer patients with bone metastasis.
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